Evotec SE to announce results for fiscal year 2023 on 24 April 2024

EQS-News: Evotec SE / Key word(s): Miscellaneous
Evotec SE to announce results for fiscal year 2023 on 24 April 2024

17.04.2024 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24
April 2024.

The Company is going to hold a conference call to discuss the results as
well as provide an update on its performance. The conference call will be
held in English.

Webcast details

Date: Wednesday, 24 April 2024
Time: 3.00 pm CEST (02.00 pm BST, 09.00 am EDT)

To join the audio webcast and to access the presentation slides, please
register via this link.

The on-demand version of the webcast will be available on our website:
www.evotec.com.

Conference call details

To join via phone, please pre-register via this link. You will then receive
a confirmation email with dedicated dial-in details such as telephone
number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialling in via phone is
available under this link.


ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec leverages this "Data-driven
R&D Autobahn to Cures" for proprietary projects and within a network of
partners including all Top 20 Pharma and over 800 biotechnology companies,
academic institutions, as well as other healthcare stakeholders. Evotec has
strategic activities in a broad range of currently underserved therapeutic
areas, including e.g. neurology, oncology, as well as metabolic and
infectious diseases. Within these areas of expertise, Evotec aims to create
the world-leading co-owned pipeline for innovative therapeutics and has
to-date established a portfolio of more than 200 proprietary and co-owned
R&D projects from early discovery to clinical development. Evotec operates
globally with more than 5,000 highly qualified people. The Company's 17
sites offer highly synergistic technologies and services and operate as
complementary clusters of excellence. For additional information please go
to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications,
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications,
Hinnerk.Rohwedder@evotec.com

IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG,
Volker.Braun@evotec.com


---------------------------------------------------------------------------

17.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1881715

End of News EQS News Service
---------------------------------------------------------------------------

1881715 17.04.2024 CET/CEST